About MedWorks

This author has not yet filled in any details.
So far MedWorks has created 122 blog entries.

New Journal Issue, VOL. 47 NO. 4, 2017, Now On-Line

By |2017-09-13T15:19:02-07:00September 13th, 2017|We Know Psychiatry|

ALL ARTICLES:  Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder By Thomas E. Brown, Emuella Flood, Phillip Sarocco, Norman Atkins, Alexandra Khachatryan Unmet Medication Coverage Needs among Adults with Attention Deficit/Hyperactivity Disorder (ADHD) By Thomas E. Brown, Emuella Flood, Phillip Sarocco, Norman Atkins, Alexandra Khachatryan [...]

Association of Lithium in Drinking Water With the Incidence of Dementia

By |2017-08-25T15:08:33-07:00August 25th, 2017|We Know Psychiatry|

Original Investigation Association of Lithium in Drinking Water With the Incidence of Dementia Lars Vedel Kessing,  Thomas Alexander Gerds,  Nikoline Nygård Knudsen, Lisbeth Flindt Jørgensen, Søren Munch Kristiansen, Denitza Voutchkova, Vibeke Ernstsen, Jörg Schullehner, Birgitte Hansen, Per Kragh Andersen, Annette Kjær Ersbøll Question  Is a higher lithium level in drinking water associated with a decreased incidence of dementia? Findings  In this Danish nationwide, population-based, [...]

AFSP: Can Ketamine Rapidly Reduce Suicidal Ideation?

By |2017-06-22T18:35:35-07:00June 22nd, 2017|We Know Psychiatry|

This work was sponsored by a Young Investigator Grant from the American Foundation for Suicide Prevention (AFSP) BACKGROUND Suicide is preventable, yet still remains a worldwide cause of death in part due to a lack of available medical interventions that can work during a suicidal crisis. Most potentially helpful medications [...]

FDA Clears New Methylphenidate Formulation for ADHD

By |2017-06-20T18:08:41-07:00June 20th, 2017|We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a new formulation of methylphenidate for children with attention-deficit/hyperactivity disorder (ADHD). Cotempla XR-ODT (Neos Therapeutics Inc) is the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of ADHD in patients aged 6 to 17 years, the company said [...]

Teen Depression Linked to Persistent Sleep-Disordered Breathing

By |2017-06-19T22:55:41-07:00June 19th, 2017|We Know Psychiatry|

By Megan Brooks BOSTON — Sleep-disordered breathing (SDB) may play a role in persistent depressive symptoms and poor response to standard pharmacologic treatments in adolescents, new research suggests. Screening adolescents with treatment-resistant depression (TRD) for SBD "may be clinically valuable, since SDB is readily treatable," said Teena Chase, MD, PhD, Department [...]

Lithium: New Uses for Old Psychotropic

By |2017-06-19T22:45:52-07:00June 19th, 2017|We Know Psychiatry|

By Nassir Ghaem Wide-Ranging Benefits At the recent American Psychiatric Association annual meeting in San Diego, an update symposium was presented on the topic of "Lithium: Key Issues for Practice."[1] In a session chaired by Dr David Osser, associate professor of psychiatry at Harvard Medical School, presenters reviewed various aspects of [...]

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

By |2017-06-19T22:30:20-07:00June 19th, 2017|We Know Psychiatry|

Original Investigation By Jari Tiihonen, MD,  Ellenor Mittendorfer-Rutz, Maila Majak; et al   Key Points Question  Are there any clinically meaningful differences between specific antipsychotic medications or routes of administration regarding the risk of psychiatric rehospitalization or other treatment failure? Findings  This database study of a nationwide cohort of patients using within-individual analysis to eliminate [...]

Experimental ADHD Drugs Aimed at Aggression, Genetic Targets

By |2017-06-14T12:51:37-07:00June 14th, 2017|We Know Psychiatry|

MIAMI – Medications in development for the treatment of attention-deficit/hyperactivity disorder (ADHD) target specific behaviors, such as impulsive aggression, and genes that involve the glutamatergic network, new research shows. In the first of two studies presented here at the American Society of Clinical Pharmacology (ASCP), researchers reported on improvements in [...]

Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial

By |2017-06-08T10:47:39-07:00June 8th, 2017|We Know Psychiatry|

Anne Katrine Pagsberg , Pia Jeppesen, Dea Gowers Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Peter Jantzen, Simone Rasmussen, Eva Ann-Sofie Saldeen, Britt Glenn Lauritsen, Niels Bilenberg, Anne Dorte Stenstrøm, Louise Nyvang , Sarah Madsen, Thomas M Werge, Theis Lange ,Christian Gluud, Maria Skoog, Peter Winkel, Jens Richardt, M Jepsen, Birgitte Fagerlund, Christoph U Correll, Anders Fink-Jensen Summary Background Head-to-head trials to guide antipsychotic treatment choices for paediatric psychosis are urgently needed because [...]